Literature DB >> 21536234

Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome.

H Sharat Chandra1, Nora C Heisterkamp, Alice Hungerford, Jennifer J D Morrissette, Peter C Nowell, Janet D Rowley, Joseph R Testa.   

Abstract

This report summarizes highlights of the Philadelphia Chromosome Symposium: Past, Present and Future, held September 28, 2010, to commemorate the 50th anniversary of the discovery of the Philadelphia chromosome. The symposium sessions included presentations by investigators who made seminal contributions concerning the discovery and molecular characterization of the Ph chromosome and others who developed a highly successful therapy based on the specific molecular alteration observed in chronic myeloid leukemia. Additional presentations highlighted future opportunities for the design of molecularly targeted therapies for various types of cancer. Also included here are reminiscences connected with the discovery of the Ph chromosome by David Hungerford and Peter Nowell, the discovery that the abnormality arises from a chromosomal translocation, by Janet Rowley, and the cloning of the 9;22 translocation breakpoints by Nora Heisterkamp, John Groffen, and colleagues.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21536234      PMCID: PMC3092778          DOI: 10.1016/j.cancergen.2011.03.002

Source DB:  PubMed          Journal:  Cancer Genet


  31 in total

1.  Cytogenetic studies in chronic myeloid leukaemia and acute leukaemia associated with monogolism.

Authors:  I M TOUGH; W M COURT BROWN; A G BAIKIE; K E BUCKTON; D G HARNDEN; P A JACOBS; M J KING; J A McBRIDE
Journal:  Lancet       Date:  1961-02-25       Impact factor: 79.321

2.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.

Authors:  E Shtivelman; B Lifshitz; R P Gale; E Canaani
Journal:  Nature       Date:  1985 Jun 13-19       Impact factor: 49.962

3.  Identificaton of a translocation with quinacrine fluorescence in a patient with acute leukemia.

Authors:  J D Rowley
Journal:  Ann Genet       Date:  1973-06

4.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

5.  Chromosomal localization of human cellular homologues of two viral oncogenes.

Authors:  N Heisterkamp; J Groffen; J R Stephenson; N K Spurr; P N Goodfellow; E Solomon; B Carritt; W F Bodmer
Journal:  Nature       Date:  1982-10-21       Impact factor: 49.962

6.  Leukocytes cultured from small inocula of whole blood and the preparation of metaphase chromosomes by treatment with hypotonic KCl.

Authors:  D A Hungerford
Journal:  Stain Technol       Date:  1965-11

7.  Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration.

Authors:  J B Konopka; S M Watanabe; J W Singer; S J Collins; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

8.  A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia.

Authors:  A de Klein; A G van Kessel; G Grosveld; C R Bartram; A Hagemeijer; D Bootsma; N K Spurr; N Heisterkamp; J Groffen; J R Stephenson
Journal:  Nature       Date:  1982-12-23       Impact factor: 49.962

Review 9.  Linking somatic genetic alterations in cancer to therapeutics.

Authors:  Darrin Stuart; William R Sellers
Journal:  Curr Opin Cell Biol       Date:  2009-03-26       Impact factor: 8.382

10.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.

Authors:  J Groffen; J R Stephenson; N Heisterkamp; A de Klein; C R Bartram; G Grosveld
Journal:  Cell       Date:  1984-01       Impact factor: 41.582

View more
  10 in total

1.  Creating cancer translocations in human cells using Cas9 DSBs and nCas9 paired nicks.

Authors:  Benjamin Renouf; Marion Piganeau; Hind Ghezraoui; Maria Jasin; Erika Brunet
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

2.  Low prevalence of the BCR-ABL1 fusion gene in a normal population in southern Sarawak.

Authors:  Jew Win Kuan; Anselm Ting Su; Siow Phing Tay; Isabel Lim Fong; Sho Kubota; Lela Su'ut; Motomi Osato; Goro Sashida
Journal:  Int J Hematol       Date:  2019-11-09       Impact factor: 2.490

3.  The President's Address: Clinical Investigation is a Pathway to Discovery.

Authors:  John A Oates
Journal:  Trans Am Clin Climatol Assoc       Date:  2012

4.  PREVENTING THE CHROMOSOMAL TRANSLOCATIONS THAT CAUSE CANCER.

Authors:  Robert Hromas; Elizabeth Williamson; Suk-Hee Lee; Jac Nickoloff
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

Review 5.  Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease.

Authors:  Kamakoti P Bhat; H Ümit Kaniskan; Jian Jin; Or Gozani
Journal:  Nat Rev Drug Discov       Date:  2021-01-19       Impact factor: 84.694

Review 6.  Targeting PI3K/AKT/mTOR network for treatment of leukemia.

Authors:  Jessika Bertacchini; Nazanin Heidari; Laura Mediani; Silvano Capitani; Mohammad Shahjahani; Ahmad Ahmadzadeh; Najmaldin Saki
Journal:  Cell Mol Life Sci       Date:  2015-02-25       Impact factor: 9.261

7.  4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines.

Authors:  Silvina Laura Lompardía; Mariángeles Díaz; Daniela Laura Papademetrio; Matías Pibuel; Élida Álvarez; Silvia Elvira Hajos
Journal:  Invest New Drugs       Date:  2016-10-08       Impact factor: 3.850

8.  A novel canine kidney cell line model for the evaluation of neoplastic development: karyotype evolution associated with spontaneous immortalization and tumorigenicity.

Authors:  R Omeir; R Thomas; B Teferedegne; C Williams; G Foseh; J Macauley; L Brinster; J Beren; K Peden; M Breen; A M Lewis
Journal:  Chromosome Res       Date:  2015-05-10       Impact factor: 5.239

9.  Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia.

Authors:  Yusuf Baran; Guray Saydam
Journal:  J Blood Med       Date:  2012-11-16

10.  Resveratrol inhibits the phosphatidylinositide 3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway in the human chronic myeloid leukemia K562 cell line.

Authors:  Tao Sui; Li Ma; Xue Bai; Qing Li; Xinnv Xu
Journal:  Oncol Lett       Date:  2014-03-28       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.